Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Standardised shorter regimens versus individualised longer regimens for multidrug-resistant TB.

Abidi S, Achar J, Neino MMA, Bang D, Benedetti A, Brode S, Campbell JR, Casas E, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Khan FA.

Eur Respir J. 2019 Dec 20. pii: 1901467. doi: 10.1183/13993003.01467-2019. [Epub ahead of print]

PMID:
31862767
2.

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.

Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M.

Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.

3.

HIV and Solid Organ Transplantation: Where Are we Now.

Botha J, Fabian J, Etheredge H, Conradie F, Tiemessen CT.

Curr HIV/AIDS Rep. 2019 Oct;16(5):404-413. doi: 10.1007/s11904-019-00460-7. Review.

4.

Needs must: living donor liver transplantation from an HIV-positive mother to her HIV-negative child in Johannesburg, South Africa.

Etheredge HR, Fabian J, Duncan M, Conradie F, Tiemessen C, Botha J.

J Med Ethics. 2019 May;45(5):287-290. doi: 10.1136/medethics-2018-105216.

5.

Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.

Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, Dawson R, Mave V, Sanchez J, Mendoza A, Gonzales P, Kumarasamy N, Comins K, Conradie F, Shenje J, Fontain SN, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo UG, Ferreira ACG, Mugah C, Harrington M, Jones L, Cox SR, Smith B, Shah NS, Hesseling AC, Churchyard G.

Clin Infect Dis. 2020 Jan 16;70(3):425-435. doi: 10.1093/cid/ciz235.

PMID:
30942853
6.

Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.

Suryavanshi N, Murrill M, Gupta A, Hughes M, Hesseling A, Kim S, Naini L, Jones L, Smith B, Gupte N, Dawson R, Mave V, Meshram S, Mendoza-Ticona A, Sanchez J, Kumarasamy N, Comins K, Conradie F, Shenje J, Nerette Fontain S, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo U, Cristina Garcia Ferreira A, Okeyo E, Swindells S, Churchyard G, Shah NS.

Clin Infect Dis. 2020 Jan 16;70(3):436-445. doi: 10.1093/cid/ciz254.

PMID:
30919881
7.

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators.

N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.

8.

Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.

Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang CY, Conradie F, Dongo JP, Heldal E, Jensen P, Nyengele JPK, Koura KG, Kumar AMV, Lin Y, Mlilo N, Nakanwagi-Mukwaya A, Ncube RT, Nyinoburyo R, Oo NL, Patel LN, Piubello A, Rusen ID, Sanda T, Satyanarayana S, Syed I, Thu AS, Tonsing J, Trébucq A, Zamora V, Zishiri C, Hinderaker SG, Aït-Khaled N, Roggi A, Caminero Luna J, Graham SM, Dlodlo RA, Fujiwara PI.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251. doi: 10.5588/ijtld.18.0207.

PMID:
30808459
9.

HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries.

Opollo VS, Wu X, Hughes MD, Swindells S, Gupta A, Hesseling A, Churchyard G, Kim S, Lando R, Dawson R, Mave V, Mendoza A, Gonzales P, Kumarasamy N, von Groote-Bidlingmaier F, Conradie F, Shenje J, Fontain SN, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Mngqibisa R, Garcia Ferreira AC, Okeyo E, Naini L, Jones L, Smith B, Shah NS.

Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1443-1449. doi: 10.5588/ijtld.18.0108.

10.

Multidrug-resistant tuberculosis outbreak in South Africa.

Ismail NA, McCarthy K, Conradie F, Stevens W, Ndjeka N.

Lancet Infect Dis. 2019 Feb;19(2):134-135. doi: 10.1016/S1473-3099(18)30715-1. Epub 2018 Dec 6. No abstract available.

PMID:
30528116
11.

Appropriate clinical use of darunavir 800 mg.

Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, Manzini T, Mathe M, Moosa Y, Nash J, Nel J, Pakade Y, Woods J, van Zyl G, Conradie F, Venter F, Meintjes G.

South Afr J HIV Med. 2018 Oct 18;19(1):918. doi: 10.4102/sajhivmed.v19i1.918. eCollection 2018. No abstract available.

12.

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy.

Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, Manzini T, Mathe M, Moosa Y, Nash J, Nel J, Pakade Y, Woods J, van Zyl G, Conradie F, Venter F, Meintjes G.

South Afr J HIV Med. 2018 Oct 17;19(1):917. doi: 10.4102/sajhivmed.v19i1.917. eCollection 2018. No abstract available.

13.

Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion.

Ferrian S, Ross M, Conradie F, Vally Omar S, Ismail N, Little F, Kaplan G, Fallows D, Gray CM.

Front Immunol. 2018 Oct 25;9:2438. doi: 10.3389/fimmu.2018.02438. eCollection 2018.

14.

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.

Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801528. doi: 10.1183/13993003.01528-2018. Print 2018 Dec.

PMID:
30361246
15.

Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.

Moorhouse M, Maartens G, Venter WDF, Moosa MY, Steegen K, Jamaloodien K, Fox MP, Conradie F.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):73-78. doi: 10.1097/QAI.0000000000001883.

16.

Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options.

Botha J, Conradie F, Etheredge H, Fabian J, Duncan M, Haeri Mazanderani A, Paximadis M, Maher H, Britz R, Loveland J, Ströbele B, Rambarran S, Mahomed A, Terblanche A, Beretta M, Brannigan L, Pienaar M, Archibald-Durham L, Lang A, Tiemessen CT.

AIDS. 2018 Oct 23;32(16):F13-F19. doi: 10.1097/QAD.0000000000002000.

17.

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.

Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, Hughes J, Ferreira H, Padanilam X, Romero R, Te Riele J, Conradie F.

Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.

PMID:
30001994
18.

Adult antiretroviral therapy guidelines 2017.

Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, Manzini T, Mathe M, Moosa Y, Nash J, Nel J, Pakade Y, Woods J, Van Zyl G, Conradie F, Venter F.

South Afr J HIV Med. 2017 Jul 15;18(1):776. doi: 10.4102/sajhivmed.v18i1.776. eCollection 2017.

19.

South African HIV self-testing policy and guidance considerations.

Venter F, Majam M, Jankelowitz L, Adams S, Moorhouse M, Carmona S, Stevens W, Msimanga BR, Allen D, Balani P, Nevhutalu Z, Rhagnath N, Shroufi A, Devillé W, Kazangarare V, van der Wiel R, Templeman H, Puren A, Tucker T, van Cutsem G, Conradie F, Dong K, Chidarikire T, Gray A.

South Afr J HIV Med. 2017 Sep 22;18(1):775. doi: 10.4102/sajhivmed.v18i1.775. eCollection 2017.

20.

Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.

Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.

Appl Health Econ Health Policy. 2018 Feb;16(1):43-54. doi: 10.1007/s40258-017-0352-8.

PMID:
28980217
21.

Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa.

Schnippel K, Firnhaber C, Ndjeka N, Conradie F, Page-Shipp L, Berhanu R, Sinanovic E.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1106-1111. doi: 10.5588/ijtld.17.0202.

PMID:
28911353
22.

A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.

Ferrian S, Manca C, Lubbe S, Conradie F, Ismail N, Kaplan G, Gray CM, Fallows D.

PLoS One. 2017 May 2;12(5):e0176660. doi: 10.1371/journal.pone.0176660. eCollection 2017.

23.

Turning the tide against tuberculosis.

Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O'Donnell MR.

Int J Infect Dis. 2017 Mar;56:6-9. doi: 10.1016/j.ijid.2017.01.012. Epub 2017 Feb 4.

24.

Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

Venter WF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, Matsolo M, Amole C, Rutter L, Abdullah F, Abrams EJ, Casas CP, Barnhart M, Pillay A, Pozniak A, Hill A, Fairlie L, Boffito M, Moorhouse M, Chersich M, Serenata C, Quevedo J, Loots G.

S Afr Med J. 2016 Dec 21;107(1):28-30. doi: 10.7196/SAMJ.2016.v107.i1.12058.

25.

Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa.

Brennan AT, Bor J, Davies MA, Conradie F, Maskew M, Long L, Sanne I, Fox MP.

Trop Med Int Health. 2017 Feb;22(2):241-251. doi: 10.1111/tmi.12811. Epub 2016 Dec 26.

26.

A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis.

Schnippel K, Ndjeka N, Conradie F, Berhanu R, Claasen Z, Banoo S, Firnhaber C.

S Afr Med J. 2016 Mar 17;106(4):30-1. doi: 10.7196/SAMJ.2016.v106i4.10205.

PMID:
27032841
27.

Tuberculosis control.

Godfrey C, Andersen J, Mngqibisa R, Scott LE, Conradie F.

Lancet. 2016 Mar 19;387(10024):1157-8. doi: 10.1016/S0140-6736(16)00706-6. No abstract available.

PMID:
27025326
28.

Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection.

Bekker LG, Rebe K, Venter F, Maartens G, Moorhouse M, Conradie F, Wallis C, Black V, Harley B, Eakles R.

South Afr J HIV Med. 2016 Mar 15;17(1):455. doi: 10.4102/sajhivmed.v17i1.455. eCollection 2016.

29.

What is the role of CD4 count in a large public health antiretroviral programme?

Moorhouse M, Conradie F, Venter F.

South Afr J HIV Med. 2016 Feb 12;17(1):446. doi: 10.4102/sajhivmed.v17i1.446. eCollection 2016. No abstract available.

30.

Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.

Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E, Maartens G.

J Antimicrob Chemother. 2016 Apr;71(4):1037-40. doi: 10.1093/jac/dkv447. Epub 2016 Jan 7.

PMID:
26747099
31.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

32.

Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy.

Meintjes G, Black J, Conradie F, Dlamini S, Maartens G, Manzini TC, Mathe M, Moorhouse M, Moosa Y, Nash J, Orrell C, Venter F, Wilson D.

South Afr J HIV Med. 2015 Dec 3;16(1):428. doi: 10.4102/sajhivmed.v16i1.428. eCollection 2015.

33.

Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update.

Moorhouse M, Bekker LG, Black V, Conradie F, Harley B, Howell P, Maartens G, Papavarnavas T, Rebe K, Sorour G, Venter F, Wallis CL.

South Afr J HIV Med. 2015 Nov 10;16(1):399. doi: 10.4102/sajhivmed.v16i1.399. eCollection 2015.

34.

Improving access to antiretrovirals in rural South Africa - a call to action.

Gray A, Conradie F, Crowley T, Gaede B, Gils T, Shroufi A, Hwang B, Kegakilwe D, Nash J, Pillay P, Stende SC, Venter F, Matthews P.

S Afr Med J. 2015 Sep 23;105(8):638-40. No abstract available.

PMID:
26449706
35.

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.

Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, Maartens G, Mametja D, Meintjes G, Padanilam X, Variava E, Pym A, Pillay Y.

Int J Tuberc Lung Dis. 2015 Aug;19(8):979-85. doi: 10.5588/ijtld.14.0944.

PMID:
26162365
36.

A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion.

Riou C, Gray CM, Lugongolo M, Gwala T, Kiravu A, Deniso P, Stewart-Isherwood L, Omar SV, Grobusch MP, Coetzee G, Conradie F, Ismail N, Kaplan G, Fallows D.

PLoS One. 2014 Jul 21;9(7):e102178. doi: 10.1371/journal.pone.0102178. eCollection 2014.

37.

Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis.

Conradie F, Meintjes G, Hughes J, Maartens G, Ferreira H, Siwendu S, Master I, Ndjeka N.

S Afr Med J. 2014 Mar;104(3):164-6.

PMID:
24897814
38.

Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection.

Dawany N, Showe LC, Kossenkov AV, Chang C, Ive P, Conradie F, Stevens W, Sanne I, Azzoni L, Montaner LJ.

PLoS One. 2014 Feb 25;9(2):e89925. doi: 10.1371/journal.pone.0089925. eCollection 2014.

39.

Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB.

Conradie F, Mabiletsa T, Sefoka M, Mabaso S, Louw R, Evans D, Van Rie A.

S Afr Med J. 2013 Oct 11;104(1):24-6. doi: 10.7196/samj.6455.

PMID:
24388081
40.

Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Eley T, Huang SP, Conradie F, Zorrilla CD, Josipovic D, Botes M, Osiyemi O, Hardy H, Bertz R, McGrath D.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1287-92. doi: 10.1089/AID.2013.0002. Epub 2013 Jul 19.

41.

Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.

Hamers RL, Straatsma E, Kityo C, Wallis CL, Stevens WS, Sigaloff KC, Siwale M, Conradie F, Botes ME, Mandaliya K, Wellington M, Osibogun A, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance.

Clin Infect Dis. 2012 May;54 Suppl 4:S261-5. doi: 10.1093/cid/cir995.

PMID:
22544185
42.

The medical proof doesn't get much better than VMMC.

Venter F, Rees H, Pillay Y, Simelela N, Mbengashe TM, Geffen N, Conradie F, Shisana O, Rech D, Serenata C, Taljaard D, Gray G.

S Afr Med J. 2012 Feb 23;102(3 Pt 1):124-5; discussion 125-6. No abstract available.

PMID:
22380896
43.

Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.

Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, Orrell C, Zeinecker J, Sanne I, Wood R, McIntyre J, Stevens W; CIPRA-SA project 1 study team.

Antivir Ther. 2012;17(2):313-20. doi: 10.3851/IMP1985. Epub 2011 Nov 18.

44.

Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.

Conradie F, Foulkes AS, Ive P, Yin X, Roussos K, Glencross DK, Lawrie D, Stevens W, Montaner LJ, Sanne I, Azzoni L.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):309-18. doi: 10.1097/QAI.0b013e31822e0d15.

45.

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.

PMID:
21802367
46.

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R.

Antivir Ther. 2011;16(4):527-34. doi: 10.3851/IMP1780.

47.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

48.

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP; CEPAC-International and OCTANE Investigators.

AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe.

49.

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, van Vugt M, Rinke de Wit TF; PharmAccess African PASER and TREAT Asia Studies to Evaluate Resistance.

Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10. No abstract available.

50.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team.

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

Supplemental Content

Loading ...
Support Center